# US 10,246,748 B2 · Biomarker combinations for colorectal tumors > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 10,246,748 B2 - Document ID: US10246748B2 - Status: Granted - Kind: B2 - Application number: 14/440,850 - Filed: 2013-11-04 - Published: 2015-10-22 - Granted: 2019-04-02 - Earliest claimed: 2012-11-05 - Assignees: Novigenix SA - Applicants: Novigenix SA - Inventors: Stavros Therianos; Curzio Ruegg; Sylvain Monnier-Benoit; Laura Ciarloni; Sahar Hosseinian - Web page: https://patentgrep.com/patent/US10246748B2 ## CPC - C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575) - G16B 5/00: ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks - G16B 5/20: Probabilistic models - G16B 25/00: ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression - G16B 25/10: Gene or protein expression profiling; Expression-ratio estimation or normalisation - G16H 50/20: for computer-aided diagnosis, e.g. based on medical expert systems - C12Q 2600/118: Prognosis of disease development - C12Q 2600/158: Expression markers - C12Q 2600/16: Primer sets for multiplex assays - Y02A 90/10: Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation - C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES - G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY - G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA - Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE ## Abstract The present invention relates to methods and kits for the detection of predetermined biomarkers for early diagnosis and management of cancer, and in particular, colorectal tumors. ## Claims ### Claim 1 A method for detecting IL1B, PTGS2 and at least one of S100A8, LTF, CXCL10, and CACNB4, the method comprising: (a) extracting RNA from blood cells in peripheral blood from a selected subject to produce extracted RNA; and (b) measuring in the extracted RNA the amount of mRNA for each biomarker in one biomarker panel, wherein the biomarker panel consists of from 3 to 29 biomarkers, wherein the 3 to 29 biomarkers comprise IL1B, PTGS2, and at least one of S100A8, LTF, CXCL10, and CACNB4, wherein said method does not comprise measuring more than 29 biomarkers. ### Claim 2 (depends on 1) The method of claim 1, wherein the subject has a history of colorectal polyps. ### Claim 3 (depends on 1) The method of claim 1, wherein the subject has ulcerative colitis or Crohn's disease. ### Claim 4 (depends on 1) The method of claim 1, wherein the subject is obese. ### Claim 5 (depends on 1) The method of claim 1, wherein the subject has a history of colorectal cancer. ### Claim 6 (depends on 1) The method of claim 1, wherein the subject has inflammatory bowel disease. ### Claim 7 (depends on 1) The method of claim 1, wherein the subject has had a positive fecal occult blood test. ### Claim 8 (depends on 1) The method of claim 1, wherein the subject does not have a history of colorectal polyps. ### Claim 9 (depends on 1) The method of claim 1, wherein the subject does not have a history of cancer. ### Claim 10 (depends on 1) The method of claim 1, wherein the subject has diabetes. ### Claim 11 (depends on 1) The method of claim 1, wherein the subject is at least 50 years old and has not been previously diagnosed or identified as having a colorectal tumor. ### Claim 12 (depends on 1) The method of claim 1, wherein the subject has as familial adenomatous polyposis (FAP), hereditary non-polyposis colon cancer (HNPCC), Turcot syndrome, Peuz-Jegher syndrome, or MUTYH-associated polyposis. ### Claim 13 (depends on 1) The method of claim 1, wherein the 3 to 29 biomarkers further comprise MMP9, CXCL11, EGR1, JUN, TNFSF13B, GATA2, MMP11, NME1, PTGES, CCR1, CXCR3, FXYD5, IL8, ITGA2, ITGB5, MAPK6, RHOC, BCL3, CD63, CES1, MAP2K3, MSL1, or PPARG. ### Claim 14 (depends on 13) The method of claim 13, wherein the 3 to 29 biomarkers consist of IL1B, PTGS2, S100A8, LTF, CXCL10, CACNB4, MMP9, CXCL11, EGR1, JUN, TNFSF13B, GATA2, MMP11, NME1, PTGES, CCR1, CXCR3, FXYD5, IL8, ITGA2, ITGB5, MAPK6, RHOC, BCL3, CD63, CES1, MAP2K3, MSL1, and PPARG. ### Claim 15 A method for detecting IL1B, PTGS2 and at least one of S100A8, LTF, CXCL10, and CACNB4, the method comprising: (a) extracting RNA from blood cells in peripheral blood from a selected subject to produce extracted RNA; and (b) measuring in the extracted RNA the amount of mRNA for each biomarker in a biomarker panel, wherein the biomarker panel comprises the biomarkers IL1B, PTGS2, and at least one of S100A8, LTF, CXCL10, and CACNB4, wherein the subject is at least 50 years old and has not been previously diagnosed or identified as having a colorectal tumor, wherein said method does not comprise measuring more than 29 biomarkers. ### Claim 16 (depends on 15) The method of claim 15, wherein the subject has a history of colorectal polyps. ### Claim 17 (depends on 15) The method of claim 15, wherein the subject has ulcerative colitis or Crohn's disease. ### Claim 18 (depends on 15) The method of claim 15, wherein the subject is obese. ### Claim 19 (depends on 15) The method of claim 15, wherein the subject has inflammatory bowel disease. ### Claim 20 (depends on 15) The method of claim 15, wherein the subject has had a positive fecal occult blood test. ### Claim 21 (depends on 15) The method of claim 15, wherein the subject does not have a history of colorectal polyps. ### Claim 22 (depends on 15) The method of claim 15, wherein the subject does not have a history of cancer. ### Claim 23 (depends on 15) The method of claim 15, wherein the subject has diabetes. ### Claim 24 (depends on 15) The method of claim 15, wherein the subject has familial adenomatous polyposis (FAP), hereditary non-polyposis colon cancer (HNPCC), Turcot syndrome, Peuz-Jegher syndrome, or MUTYH-associated polyposis.